Ultrasonography surveillance improves prognosis of patients with hepatocellular carcinoma

被引:1
作者
Yamago, Hiroka [1 ]
Hiraoka, Atsushi [1 ]
Murakami, Taisei [1 ]
Izumoto, Hirofumi [1 ]
Ueki, Hidetaro [1 ]
Ochi, Marie [1 ]
Aibiki, Toshihiko [1 ]
Okudaira, Tomonari [1 ]
Iwasaki, Ryuichiro [1 ]
Suga, Yoshifumi [1 ]
Mori, Kenichiro [1 ]
Miyata, Hideki [1 ]
Tsubouchi, Eiji [1 ]
Kishida, Masato [1 ]
Hirooka, Masashi [2 ]
Abe, Masanori [2 ]
Matsuura, Bunzo [2 ]
Ninomiya, Tomoyuki [1 ]
Hiasa, Yoichi [2 ]
Michitaka, Kojiro [1 ]
机构
[1] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, 83 Kasuga Cho, Matsuyama, Ehime 7900024, Japan
[2] Ehime Univ, Grad Sch Med, Dept Gastroenterol & Metabol, Toon, Ehime 7910295, Japan
关键词
hepatocellular carcinoma; surveillance; ultrasonography; CONTRAST-ENHANCED ULTRASONOGRAPHY; RADIOFREQUENCY ABLATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; CLINICAL CHARACTERISTICS; NON-B; SORAFENIB; DIAGNOSIS; FIBROSIS; CANCER; GRADE;
D O I
10.3892/mco.2019.1888
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To examine the effectiveness of ultrasonography (US) for hepatocellular carcinoma (HCC) surveillance, the prognosis of HCC patients who underwent such screening at an expert medical institution or at general clinics were analyzed, as well as those without US surveillance. From October 2006 to December 2014, 872 patients with naive HCC were enrolled and divided into the surveillance (S)-group (n=398), who underwent follow-up examinations with US, and the non-S group (n=474). The S-group was further subdivided into patients who underwent follow-up surveillance at Ehime Prefectural Central Hospital, an expert medical institution (SE-group, n=189), and those who received surveillance at general clinics (SG-group, n=209). Prognosis and clinical characteristics were analyzed. In the non-S group, the frequency of patients without viral hepatitis (NBNC-HCC) and Tumor, Node, Metastasis stage was greater. As a result, the median survival time (MST) of the non-S group was reduced, compared with the S group (non-S group, 34.1 vs. S group, 68.2 months; P<0.001). Tumor size was significantly different between the SE- and SG-groups (SE-group, 2.0 +/- 1.0 vs. SG-group, 2.5 +/- 1.3 cm; P<0.001), whereas tumor number (SE-group: 1.5 +/- 1.1 vs. SG-group, 1.7 +/- 1.2; P=0.164) and MST (SE-group, 72.1 vs. SG-group, 67.1 months; P=0.931) were not significantly different. Surveillance performed at either an expert medical institution or general clinic improved the prognosis of HCC patients. Dissemination of findings demonstrating the importance of surveillance for HCC to all clinicians as well as patients with chronic liver disease is important, and establishment of an effective surveillance strategy for NBNC-HCC is required.
引用
收藏
页码:325 / 330
页数:6
相关论文
共 41 条
[1]   Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis [J].
Bolondi, L ;
Sofia, S ;
Siringo, S ;
Gaiani, S ;
Casali, A ;
Zironi, G ;
Piscaglia, F ;
Gramantieri, L ;
Zanetti, M ;
Sherman, M .
GUT, 2001, 48 (02) :251-259
[2]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[3]   Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Bruix, Jordi ;
Qin, Shukui ;
Merle, Philippe ;
Granito, Alessandro ;
Huang, Yi-Hsiang ;
Bodoky, Gyrogy ;
Pracht, Marc ;
Yokosuka, Osamu ;
Rosmorduc, Olivier ;
Breder, Valeriy ;
Gerolami, Rene ;
Masi, Gianluca ;
Ross, Paul J. ;
Song, Tianqiang ;
Bronowicki, Jean-Pierre ;
Ollivier-Hourmand, Isabelle ;
Kudo, Masatoshi ;
Cheng, Ann-Lii ;
Llovet, Josep M. ;
Finn, Richard S. ;
LeBerre, Marie-Aude ;
Baumhauer, Annette ;
Meinhardt, Gerold ;
Han, Guohong .
LANCET, 2017, 389 (10064) :56-66
[4]   Screening for liver cancer: results of a randomised controlled trial in Qidong, China [J].
Chen, JG ;
Parkin, DM ;
Chen, QG ;
Lu, JH ;
Shen, QJ ;
Zhang, BC ;
Zhu, YR .
JOURNAL OF MEDICAL SCREENING, 2003, 10 (04) :204-209
[5]   Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study [J].
Costentin, Charlotte E. ;
Layese, Richard ;
Bourcier, Valerie ;
Cagnot, Carole ;
Marcellin, Patrick ;
Guyader, Dominique ;
Pol, Stanislas ;
Larrey, Dominique ;
De Ledinghen, Victor ;
Ouzan, Denis ;
Zoulim, Fabien ;
Roulot, Dominique ;
Tran, Albert ;
Bronowicki, Jean-Pierre ;
Zarski, Jean-Pierre ;
Riachi, Ghassan ;
Cales, Paul ;
Peron, Jean-Marie ;
Alric, Laurent ;
Bourliere, Marc ;
Mathurin, Philippe ;
Blanc, Jean-Frederic ;
Abergel, Armand ;
Serfaty, Lawrence ;
Mallat, Ariane ;
Grange, Jean-Didier ;
Attali, Pierre ;
Bacq, Yannick ;
Wartelle, Claire ;
Dao, Thong ;
Thabut, Dominique ;
Pilette, Christophe ;
Silvain, Christine ;
Christidis, Christos ;
Nguyen-khac, Eric ;
Bernard-Chabert, Brigitte ;
Zucman, David ;
Di Martino, Vincent ;
Sutton, Angela ;
Letouze, Eric ;
Imbeaud, Sandrine ;
Zucman-Rossi, Jessica ;
Audureau, Etienne ;
Roudot-Thoraval, Francoise ;
Nahon, Pierre .
GASTROENTEROLOGY, 2018, 155 (02) :431-+
[6]   Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis [J].
Hiraoka, Atsushi ;
Kumada, Takashi ;
Kariyama, Kazuya ;
Takaguchi, Koichi ;
Itobayashi, Ei ;
Shimada, Noritomo ;
Tajiri, Kazuto ;
Tsuji, Kunihiko ;
Ishikawa, Toru ;
Ochi, Hironori ;
Hirooka, Masashi ;
Tsutsui, Akemi ;
Shibata, Hiroshi ;
Tada, Toshifumi ;
Toyoda, Hidenori ;
Nouso, Kazuhiro ;
Joko, Kouji ;
Hiasa, Yoichi ;
Michitaka, Kojiro .
HEPATOLOGY RESEARCH, 2019, 49 (01) :111-117
[7]   Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications [J].
Hiraoka, Atsushi ;
Kumada, Takashi ;
Kudo, Masatoshi ;
Hirooka, Masashi ;
Tsuji, Kunihiko ;
Itobayashi, Ei ;
Kariyama, Kazuya ;
Ishikawa, Toru ;
Tajiri, Kazuto ;
Ochi, Hironori ;
Tada, Toshifumi ;
Toyoda, Hidenori ;
Nouso, Kazuhiro ;
Joko, Kouji ;
Kawasaki, Hideki ;
Hiasa, Yoichi ;
Michitaka, Kojiro .
LIVER CANCER, 2017, 6 (03) :204-215
[8]   Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma [J].
Hiraoka, Atsushi ;
Kumada, Takashi ;
Michitaka, Kojiro ;
Toyoda, Hidenori ;
Tada, Toshifumi ;
Ueki, Hidetaro ;
Kaneto, Miho ;
Aibiki, Toshihiko ;
Okudaira, Tomonari ;
Kawakami, Takamasa ;
Kawamura, Tomoe ;
Yamago, Hiroka ;
Suga, Yoshifumi ;
Miyamoto, Yuji ;
Tomida, Hideomi ;
Azemoto, Nobuaki ;
Mori, Kenichiro ;
Miyata, Hideki ;
Ninomiya, Tomoyuki ;
Kawasaki, Hideki .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 (05) :1031-1036
[9]   Ultrasonography screening for hepatocellular carcinoma in Japanese patients with diabetes mellitus [J].
Hiraoka, Atsushi ;
Ochi, Marie ;
Matsuda, Rie ;
Aibiki, Toshihiko ;
Okudaira, Tomonari ;
Kawamura, Tomoe ;
Yamago, Hiroka ;
Nakahara, Hiromasa ;
Suga, Yoshifumi ;
Azemoto, Nobuaki ;
Miyata, Hideki ;
Miyamoto, Yasunao ;
Ninomiya, Tomoyuki ;
Hirooka, Masashi ;
Abe, Masanori ;
Matsuura, Bunzo ;
Hiasa, Yoichi ;
Michitaka, Kojiro .
JOURNAL OF DIABETES, 2016, 8 (05) :640-646
[10]   Recent Trends of Japanese Hepatocellular Carcinoma due to HCV in Aging Society [J].
Hiraoka, Atsushi ;
Hidaka, Satoshi ;
Shimizu, Yuko ;
Utsunomiya, Hiroki ;
Imai, Yusuke ;
Tatsukawa, Haruka ;
Tazuya, Nayu ;
Yamago, Hiroka ;
Yorimitsu, Nobukazu ;
Tanihira, Tetsuya ;
Hasebe, Aki ;
Miyamoto, Yasunao ;
Ninomiya, Tomoyuki ;
Kawasaki, Hideki ;
Hirooka, Masashi ;
Abe, Masanori ;
Hiasa, Yoichi ;
Matsuura, Bunzo ;
Onji, Morikazu ;
Michitaka, Kojiro .
HEPATO-GASTROENTEROLOGY, 2012, 59 (118) :1893-1895